PSA Test & Comprehensive Prostate Health Screening London 2026: London's Premier Doctor-Led Pathway
Reviewed by the medical team at The Online GP by The Wellness | Last updated: April 2026 | GMC-registered doctors | clinic | 10 Portman Square, Marylebone, London W1H 6AZ
At a glance
The Online GP by The Wellness offers London's premier doctor-led PSA test and comprehensive prostate health screening pathway, with pricing aligned with the leading central London urology clinics and a clinical model built to the standards expected by the most demanding patients. Our pathway is fully compliant with NICE Guideline NG131 (prostate cancer diagnosis and management) and the British Association of Urological Surgeons (BAUS) guidance, and includes structured pre-test counselling, PSA blood test, digital rectal examination by a GMC-registered doctor where indicated, advanced Stockholm3 testing where requested, and direct multiparametric MRI and consultant urology referral pathway for any abnormal result.
Book today: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com | Call 020 3951 3429
Why is prostate screening one of the most important conversations a man over 45 should have?
Prostate cancer is the most common cancer in men in the UK. According to Prostate Cancer UK and Cancer Research UK, around 55,000 UK men are diagnosed with prostate cancer each year, and 1 in 8 UK men will develop the disease in their lifetime. The risk rises substantially with age (median age at diagnosis is 67 years), with family history (a first-degree relative diagnosed before age 65 doubles risk), and with Black African or Black Caribbean ethnicity (where lifetime risk is approximately 1 in 4, compared with 1 in 8 in the general population). Despite the prevalence, around 1 in 3 UK prostate cancers are diagnosed at a stage where curative treatment is more difficult, often because early disease is silent.
The clinical message is nuanced rather than simple. Unlike skin cancer screening (where the right answer is always to look more closely) or cholesterol screening (where lower is reliably better), prostate screening involves a genuine balance. The PSA blood test is imperfect: around 3 in 4 men with raised PSA do not have cancer, and a small proportion of significant prostate cancers do not raise PSA appreciably. Overdiagnosis (finding indolent cancers that would never cause harm) and overtreatment (operating on cancers that did not need treatment) have been real harms of poorly counselled population PSA screening, and this is why the UK does not have a national PSA screening programme.
What the UK does have, set out in NICE Guideline NG131 and the recent national Prostate Cancer Risk Management Programme update, is a recommended approach of informed-choice PSA testing for men aged 50 and over (or 45 and over for higher-risk groups) following structured pre-test counselling. The 2024 TRANSFORM trial and emerging evidence on multiparametric MRI as a second-stage diagnostic tool have substantially refined this pathway. Modern UK prostate screening combines: structured risk assessment, careful pre-test counselling, baseline PSA, free-to-total PSA ratio, digital rectal examination, and where indicated, advanced biomarker testing (such as Stockholm3) and multiparametric prostate MRI before any biopsy decision.
The Online GP by The Wellness delivers this pathway with the clinical care London's most demanding patients expect. Our doctors take time to discuss the genuine balance of benefits and harms before testing, perform structured digital rectal examination where indicated, integrate PSA results with broader cardiovascular and metabolic risk assessment, and refer to leading London consultant urologists and uro-radiologists for any abnormal result. The pathway is fully aligned with NICE NG131, the British Association of Urological Surgeons (BAUS), the European Association of Urology (EAU) 2024 prostate cancer guidelines, and Prostate Cancer UK clinical recommendations.
Want a doctor-led conversation about whether to have a PSA test? WhatsApp +44 7961 280835
What is PSA and what should the test result mean?
PSA (prostate-specific antigen) is a protein produced almost exclusively by prostate tissue. PSA is measured in nanograms per millilitre (ng/mL) of blood. PSA levels rise with prostate cancer, but also with benign prostatic hyperplasia (BPH, the non-cancerous enlargement that is universal with ageing), prostatitis (inflammation), urinary tract infection, recent ejaculation, recent vigorous exercise (particularly cycling), recent prostate examination or instrumentation, and certain medications.
NICE-recommended age-stratified PSA upper limits for further investigation in men without symptoms are approximately:
Men aged 50 to 59: PSA above 3.0 ng/mL warrants further evaluation
Men aged 60 to 69: PSA above 4.0 ng/mL warrants further evaluation
Men aged 70 and over: PSA above 5.0 ng/mL warrants further evaluation
Men under 50: lower threshold typically applies, with consideration of family history, ethnicity, and clinical context
The free-to-total PSA ratio refines interpretation. PSA exists in the blood in two principal forms: free PSA and complexed PSA. In benign conditions (BPH, prostatitis), a higher proportion of PSA is in the free form. In prostate cancer, a higher proportion is complexed. A free PSA percentage below 15% (in men with total PSA between 4 and 10) increases the probability of cancer and supports proceeding to imaging or biopsy; a free PSA percentage above 25% supports observation. The Online GP by The Wellness includes free PSA measurement in the £95 panel and the £495 comprehensive package.
PSA velocity (the rate of rise over time) and PSA density (the PSA value adjusted for prostate volume measured on imaging) provide further refinement, used by urology specialists in interpreting borderline results. The doctors at The Online GP by The Wellness apply this clinical context rather than simply reporting a single number.
Important context that matters: A single raised PSA does not mean cancer, and a normal PSA does not exclude cancer. The clinical decision to proceed to multiparametric MRI, advanced biomarker testing (Stockholm3, 4Kscore, PHI), or biopsy is informed by the entire clinical picture, family history, ethnicity, prior PSA values, free-to-total ratio, examination findings, and the patient's individual values about diagnosis and treatment.
What is Stockholm3 and how does it refine the pathway?
Stockholm3 is an advanced prostate cancer risk test that combines five protein biomarkers (including total PSA, free PSA, intact PSA, hK2, and MSMB), genetic markers (single nucleotide polymorphisms), and clinical data (age, family history, prior biopsy) in a validated algorithm. The test was developed at the Karolinska Institute in Sweden and validated in the STHLM3 trial (Lancet Oncology 2015) and subsequent independent cohorts.
The clinical advantage of Stockholm3 over standalone PSA testing is more accurate identification of men with clinically significant prostate cancer (Gleason grade group 2 or above), with reduction in unnecessary biopsies of indolent disease. Published validation studies suggest Stockholm3 reduces the need for biopsy by approximately 30% to 45% compared with PSA-only pathways, while detecting the same number or more clinically significant cancers. A Stockholm3 risk score of 11 or above indicates significantly elevated cancer risk and supports proceeding to multiparametric MRI and consultant urology assessment.
The Online GP by The Wellness offers Stockholm3 testing at £495 standalone (test only, with brief result discussion) or £695 as part of the full advanced pathway including pre-test counselling, examination, integrated risk assessment, written report, and onward referral coordination. Stockholm3 is particularly valuable for: men with borderline PSA results (4 to 10 ng/mL); men with strong family history of prostate cancer; men of Black African or Black Caribbean heritage; men whose prior biopsy was negative but who have ongoing PSA elevation; and men who want the most refined risk stratification before any biopsy decision.
For men whose risk profile, PSA, or Stockholm3 indicates moderate or high cancer risk, the next investigation is typically multiparametric prostate MRI rather than direct biopsy. This is the major change in UK prostate cancer pathway over the past decade and is supported by NICE NG131, EAU guidance, and the PROMIS trial published in The Lancet.
Considering Stockholm3 advanced testing? WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com
Who should consider PSA testing and when?
Following NICE NG131, the Prostate Cancer Risk Management Programme, and BAUS guidance, the following groups should be offered structured pre-test counselling and informed-choice PSA testing in 2026.
Highest-priority groups (consider PSA testing from age 45):
Men with first-degree family history of prostate cancer, particularly diagnosed under 65
Men of Black African or Black Caribbean heritage (lifetime risk approximately 1 in 4)
Men with known BRCA1 or BRCA2 mutation, or other relevant genetic predisposition
Men with multiple family members affected by prostate, breast, or ovarian cancer (potential hereditary cancer syndrome)
Standard population (consider PSA testing from age 50):
All men aged 50 and over who request testing following structured counselling
Men aged 50 and over with lower urinary tract symptoms (frequency, urgency, hesitancy, weak flow, nocturia, incomplete emptying), who should also be assessed for BPH
Men with symptoms suggesting prostate cancer (immediate testing regardless of age):
Persistent unexplained lower back, hip, or pelvic pain in older men
Bone pain in men with cardiovascular risk profile and prior unexplained ill-health
Haematuria (blood in urine), particularly with negative urology workup elsewhere
Erectile dysfunction with concerning examination findings (see our Erectile Dysfunction & Men's Sexual Health London 2026 guide)
Unexplained anaemia or weight loss in older men
Men with elevated risk profile from broader assessment:
Patients on TRT (testosterone replacement therapy) where structured PSA monitoring is part of safe prescribing (see our TRT London 2026 guide)
Patients in executive health assessment programmes where prostate health is a baseline component
Patients with hereditary cancer syndromes identified on genetic testing
When PSA testing is generally not recommended:
Men under 40 without significant family history or genetic predisposition (very low cancer prevalence; risk of false positives high)
Men over 75 to 80 with limited life expectancy from comorbidity, where any cancer found would not benefit from treatment
Men with known active urinary tract infection or recent prostate procedure (PSA artificially raised)
The right answer for any individual man is informed by structured counselling, family history, ethnicity, prior testing, and personal values. The Online GP by The Wellness consultation includes this counselling as a core element, not an afterthought.
What does the Comprehensive Prostate Health Package include?
The Comprehensive Prostate Health Package at The Online GP by The Wellness costs £495 and is structured to deliver the same clinical rigour patients would receive at the leading London consultant urology clinics, with the integrated continuity of care that comes from being part of the broader Wellness primary care relationship.
The £495 package includes:
A 30-minute consultation with a GMC-registered doctor, including focused medical and family history, lifestyle review, ethnicity-stratified risk assessment, lower urinary tract symptom (LUTS) review using IPSS (International Prostate Symptom Score), discussion of testosterone status if relevant, prior PSA and prostate examination history, and structured pre-test counselling on the benefits and limitations of PSA testing
PSA blood test with free-to-total PSA ratio, processed at our partner laboratory The Doctors Laboratory (TDL) with results returned in 24 to 48 hours
Digital rectal examination (DRE) by the GMC-registered doctor where indicated and consented to (DRE adds clinical value because some prostate cancers and other prostate pathology can be palpable even when PSA is normal)
Urinalysis to exclude infection or haematuria as a confounding factor
Cardiovascular and metabolic risk assessment integrated where appropriate (prostate health is closely connected to overall cardiovascular and metabolic health)
Body composition including weight, BMI, waist circumference
Personalised written report issued within 3 working days, summarising findings, results interpretation, treatment or investigation recommendations, and clear next steps
Direct multiparametric MRI referral pathway through trusted London uro-radiology partners where indicated
Direct consultant urology referral typically within 48 to 72 hours where indicated
Follow-up consultation by phone or video included
The £695 advanced package adds Stockholm3 risk assessment to the comprehensive workup. The £795 Comprehensive Prostate Plus integrates multiparametric prostate MRI referral coordination and structured consultant urology pathway management for men with elevated risk indicators.
Want a thoughtful conversation before booking? WhatsApp +44 7961 280835
What does multiparametric prostate MRI add?
Multiparametric MRI (mpMRI) of the prostate is the major diagnostic advance in modern prostate cancer pathway. The technique combines several MRI sequences (T2-weighted imaging, diffusion-weighted imaging, dynamic contrast enhancement) to produce a detailed map of the prostate, with suspicious areas scored on the PI-RADS (Prostate Imaging Reporting and Data System) scale of 1 to 5.
The clinical value of mpMRI was established in the PROMIS trial (Lancet 2017) and PRECISION trial (NEJM 2018), which together showed that performing mpMRI before biopsy significantly reduces unnecessary biopsies, improves detection of clinically significant cancer, and reduces overdiagnosis of indolent disease. NICE NG131 now recommends mpMRI as the first-line diagnostic test in men with suspected prostate cancer, before any biopsy decision in most cases.
How the PI-RADS score guides next steps:
PI-RADS 1 to 2: low or very low probability of clinically significant cancer; biopsy typically not indicated; PSA monitoring continues
PI-RADS 3: equivocal; clinical decision based on PSA density, family history, and consultant judgement
PI-RADS 4 to 5: moderate to high probability of clinically significant cancer; targeted biopsy indicated, typically transperineal under local or general anaesthetic
The Online GP by The Wellness coordinates referral to leading London uro-radiology partners performing mpMRI to a UK national standard, typically £750 to £1,200 for the scan with consultant report. We integrate the MRI findings with our clinical assessment and coordinate consultant urology referral for definitive management decisions.
How does The Wellness compare with other London prostate screening providers?
London is one of the world's leading centres for private urology, with several outstanding clinics. The Online GP by The Wellness sits alongside the leading London urology providers, with pricing aligned with the top tier and a service model that emphasises GP-led primary care continuity, structured counselling, and direct consultant pathway access.
ProviderPSA test onlyComprehensive prostate packagePathwayThe Online GP by The Wellness£59£295 / £495 / £695 (Stockholm3) / £795 PlusDoctor-led GP, GMC, multilingual, Marylebone, integrated care, consultant referralPhoenix Hospital Group (Harley Street)bespoke£650 (two consultations + tests)Consultant urologist-led, Harley StreetHCA UK Healthcarebespoke£500–£1,000+Hospital-based, consultant urologist-ledOneWelbeck Urology£200+ consultation£600–£1,500 packagesConsultant-led, premiumThe London Clinicbespoke£700–£1,500Hospital-based, premiumCromwell Hospitalbespoke£600–£1,200BUPA-owned, consultant-ledSantis Health (HCA Shard)£250–£350bespokeSpecialist prostate diagnostic serviceGenesis Care£150+ consultationvariesSpecialist cancer centre108 Harley Street Men's Health£200+ consultation£400–£800Specialist men's health
The Online GP by The Wellness is positioned as a premium, doctor-led, integrated alternative to consultant-only urology services, with a complete pathway that connects directly to consultant urologists and uro-radiologists for any indicated specialist work. The differentiators that matter most to our patients in 2026:
Doctor-led structured pre-test counselling, the part most commonly under-delivered in commodity PSA testing services
GMC-registered doctors performing examination, with multilingual care in English, Arabic, Spanish, French, and Dutch
Same-day or same-week appointments typically available
Integrated continuity of care: prostate screening sits alongside our broader services including TRT, ED treatment, executive health, comprehensive blood panels, GP, family medicine
Marylebone medical clinic at 10 Portman Square, in central London's premier medical and embassy district
Stockholm3 advanced testing offered in-house with structured clinical interpretation
Direct multiparametric MRI referral pathway through leading London uro-radiology partners
Direct consultant urology referral pathway typically within 48 to 72 hours
Pricing aligned with London's leading private urology providers with transparent costs and no hidden fees
Aligned with NICE NG131, BAUS, EAU 2024, and Prostate Cancer UK guidance
For men who want consultant-only urology from the outset, we work alongside leading London urology consultants. For men who want a comprehensive doctor-led screening pathway integrated with broader healthcare, The Online GP by The Wellness is built for that need.
Considering different providers? Have a free 5-minute call: WhatsApp +44 7961 280835
What about benign prostatic hyperplasia (BPH) and lower urinary tract symptoms?
The most common cause of lower urinary tract symptoms (LUTS) in men over 50 is benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the prostate that is essentially universal with ageing. BPH affects approximately 50% of men in their 60s and 80% of men in their 80s. The clinical presentation is typically: increased urinary frequency, urgency, weak flow, hesitancy, post-void dribbling, nocturia (waking to urinate at night), and incomplete bladder emptying.
The Online GP by The Wellness assessment includes structured BPH evaluation alongside any prostate cancer screening discussion. We use the IPSS (International Prostate Symptom Score) to quantify symptoms, distinguish BPH from other causes of LUTS (urinary tract infection, overactive bladder, diabetes, neurological causes), and develop a treatment plan tailored to the severity and impact on quality of life.
BPH treatment options include:
Lifestyle modification: fluid management, caffeine and alcohol moderation, bladder training, pelvic floor exercises, weight loss
Alpha-blockers (tamsulosin, alfuzosin, doxazosin): reduce smooth muscle tone in the prostate and bladder neck, improving urinary flow
5-alpha reductase inhibitors (finasteride, dutasteride): reduce prostate size over months; can lower PSA by approximately 50%, which must be accounted for in screening decisions
Combination therapy: alpha-blocker plus 5-alpha reductase inhibitor for moderate to severe BPH
Tadalafil 5mg daily: licensed for both BPH and erectile dysfunction; particularly useful where both conditions coexist
Surgical interventions: TURP, HoLEP, UroLift, REZUM, prostate artery embolisation, robotic simple prostatectomy, all offered through consultant urology partners
The Online GP by The Wellness manages medical BPH treatment through the doctor-led pathway and refers to consultant urology partners for surgical evaluation where indicated.
What if biopsy is recommended?
Where multiparametric MRI shows a PI-RADS 4 or 5 lesion (or selected PI-RADS 3 lesions in higher-risk contexts), targeted prostate biopsy is the next investigation. The standard UK approach in 2026 is transperineal biopsy under local or general anaesthetic, which has lower infection rates and better access to anterior prostate compared to the older transrectal approach.
The transperineal biopsy procedure typically takes 20 to 40 minutes, is performed at a consultant urologist's clinic or partner hospital, and uses image fusion (combining the MRI map with real-time ultrasound) to target biopsies precisely to the suspicious areas. Cost is typically £2,000 to £4,000 including consultant fee, theatre, anaesthetic, biopsies, and histopathology. Most major UK insurers cover biopsy when clinically indicated.
The Online GP by The Wellness coordinates this pathway through leading London uro-oncology consultants and can support patients through the entire process, including pre-procedure preparation, post-procedure recovery, integration of the histology result into ongoing care, and onward management decisions including active surveillance for low-risk disease, focal therapy, robotic prostatectomy, radiotherapy, or hormone therapy as indicated by stage and patient preference.
For active surveillance (the appropriate management for many low-risk prostate cancers, defined by Gleason 6/grade group 1 disease, low-volume, organ-confined), structured monitoring includes regular PSA, repeat MRI, and repeat biopsy if indicated. The Wellness can deliver the PSA monitoring and integrate consultant uro-oncology surveillance.
Frequently asked questions
How much does private prostate screening cost in London?
At The Online GP by The Wellness, a standalone PSA test is £59, free PSA / total PSA ratio panel is £95, GP consultation with PSA discussion is £79, comprehensive prostate health consultation including DRE is £295, the full Comprehensive Prostate Health Package is £495, Stockholm3 advanced pathway is £695, and Comprehensive Prostate Plus including mpMRI coordination is £795 (with mpMRI itself £750–£1,200 at partner imaging centres). Pricing is aligned with London's leading private urology providers.
Should I have a PSA test?
The decision to have a PSA test is individual and benefits from structured pre-test counselling. Most men aged 50 and over should consider it after counselling. Men aged 45 and over with first-degree family history of prostate cancer, men of Black African or Black Caribbean heritage, and men with BRCA1/BRCA2 mutations should consider testing earlier. Men under 40 without significant family history typically do not benefit from testing. The Online GP by The Wellness provides this counselling as a core element of every prostate consultation.
Will a digital rectal examination (DRE) be performed?
The Online GP by The Wellness offers DRE as a standard part of the comprehensive prostate consultation where clinically indicated, with full patient consent. DRE adds clinical information that PSA alone does not, particularly the texture and contour of the prostate. Patients who prefer not to have DRE can decline; we will continue with PSA-led screening alone, with appropriate clinical interpretation.
What is Stockholm3 and is it worth the additional cost?
Stockholm3 is an advanced prostate cancer risk test combining PSA, additional protein biomarkers, genetic markers, and clinical data to refine risk stratification. It is particularly valuable for men with borderline PSA (4 to 10), strong family history, Black African/Caribbean heritage, or prior negative biopsy with persistent PSA elevation. Published validation suggests Stockholm3 reduces unnecessary biopsies by 30 to 45% while maintaining detection of clinically significant cancer. Stockholm3 testing through The Online GP by The Wellness is £495 standalone or £695 within a full advanced pathway.
What if my PSA is high?
A raised PSA does not mean cancer (around 3 in 4 men with raised PSA do not have cancer). The next steps depend on the specific value, age, family history, examination findings, and free-to-total PSA ratio. The Online GP by The Wellness coordinates referral to multiparametric MRI through leading London uro-radiology partners (typically within 1 to 2 weeks), with consultant urology assessment if MRI shows a suspicious lesion. The pathway is structured to deliver definitive answer in the shortest clinically appropriate time.
Can my insurance cover prostate screening?
Most major UK private medical insurers (Bupa, AXA, Vitality, WPA, Aviva) cover prostate investigation when there is a clinical indication such as raised PSA, family history, lower urinary tract symptoms, or referral by a GP. Pure preventive screening for asymptomatic patients is typically self-pay. Higher-tier and global policies (Bupa Global, Cigna Global, Aetna International) often cover preventive screening. We provide structured receipts to support insurance claims.
How does Wellness compare with HCA, OneWelbeck, or Phoenix Hospital?
The Online GP by The Wellness sits alongside HCA, OneWelbeck, Phoenix Hospital Group, The London Clinic, Cromwell Hospital, and Santis Health as a leading London prostate screening provider. Pricing is aligned with these top-tier providers (£295 to £795 across the comprehensive packages, with mpMRI referred to consultant partner). Our distinctive position is the doctor-led primary care continuity model, where prostate screening sits within an ongoing relationship that includes TRT, ED treatment, executive health, comprehensive blood panels, family medicine, and broader GP services.
What about prostate health in men on TRT?
Men on testosterone replacement therapy require structured PSA monitoring as part of safe prescribing per BSSM and EAU guidance. The Online GP by The Wellness integrates prostate screening into TRT management, with baseline PSA before starting TRT, repeat PSA at 3 to 6 months and 12 months, and annual surveillance thereafter. Significant rise in PSA on TRT prompts pause, mpMRI, and consultant urology assessment. See our TRT London 2026 guide for full TRT pathway detail.
Are appointments multilingual?
Yes. GMC-registered doctors at The Online GP by The Wellness consult in English, Arabic, Spanish, French, and Dutch. For other languages, we coordinate professional medical interpreters arranged in advance. Multilingual prostate consultation matters because many men find the conversation easier and more accurate in their first language.
Why The Online GP by The Wellness for prostate screening in 2026?
The Online GP by The Wellness brings together the elements that matter for accurate, dignified, structured prostate health screening: GMC-registered doctors, structured pre-test counselling aligned with NICE NG131, comprehensive PSA testing including free-to-total ratio, Stockholm3 advanced testing, direct multiparametric MRI and consultant urology referral pathway, and the multilingual, central London setting that high-net-worth, embassy, expat, and visiting patients expect.
What sets us apart in 2026:
Doctor-led structured pre-test counselling, the part most consistently under-delivered in commodity PSA testing
GMC-registered doctors performing consultation, examination, and clinical interpretation
Marylebone medical clinic at 10 Portman Square, in central London's premier medical district
Same-week appointments with same-day options typically available
Pricing aligned with London's leading private urology providers with transparent costs
Stockholm3 advanced biomarker testing offered with structured clinical interpretation
Direct multiparametric MRI referral pathway through leading London uro-radiology partners
Direct consultant urology and uro-oncology referral pathway typically within 48 to 72 hours
Integration with broader services including TRT, ED treatment, executive health, comprehensive blood panels, family medicine
Multilingual care in English, Arabic, Spanish, French, and Dutch
Aligned with NICE NG131, BAUS, EAU 2024, and Prostate Cancer UK guidance
For UK residents wanting fast access without NHS waits; for men with positive family history, Black African/Caribbean heritage, or BRCA mutation; for executives wanting a thorough baseline; for international patients consolidating a comprehensive workup in London; and for men with lower urinary tract symptoms wanting both BPH and cancer assessment, the Comprehensive Prostate Health Package at The Online GP by The Wellness is among the most clinically rigorous available in London in 2026.
Book your prostate health consultation today
Same-week appointments are usually available; same-day slots are often available for urgent clinical concerns. Multilingual GMC-registered doctors, structured pre-test counselling, comprehensive PSA and DRE assessment, and direct mpMRI and consultant urology referral pathway when indicated.
WhatsApp: Message +44 7961 280835 for a same-day reply.
Email: team@thewellnesslondon.com
Phone: 020 3951 3429
In-person: The Wellness, 10 Portman Square, Marylebone, London W1H 6AZ. Opening hours: Monday to Friday 8am–8pm, Saturday 9am–5pm.
Related guides at The Wellness
TRT London 2026: Testosterone Replacement Therapy Doctor-Led Pathway
Executive Health Screening London 2026: Comprehensive Body Scan Packages
Comprehensive Blood Tests London 2026: Lifestyle, Hormones, and Advanced Panels
International Patient Concierge Healthcare London 2026: Multilingual Premium Service
References and further reading
NICE Guideline NG131: Prostate cancer: diagnosis and management
NICE Diagnostics Guidance on multiparametric MRI in prostate cancer
British Association of Urological Surgeons (BAUS) prostate cancer guidance
European Association of Urology (EAU) prostate cancer guidelines, 2024 update
Prostate Cancer UK clinical recommendations
Prostate Cancer Risk Management Programme (UK)
PROMIS trial (Lancet 2017) and PRECISION trial (NEJM 2018) on multiparametric MRI
STHLM3 trial (Lancet Oncology 2015) on Stockholm3 risk model
TRANSFORM trial 2024 on screening pathway optimisation
The Doctors Laboratory clinical reference ranges and methodology
Cancer Research UK prostate cancer statistics 2026
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Prostate screening decisions should be individualised based on personal and family risk factors, ethnicity, comorbidities, and personal values about diagnosis and treatment. The Wellness is a private healthcare clinic with GMC-registered doctors. Multiparametric prostate MRI and biopsy are arranged through consultant uro-radiology and urology partners. For acute urinary retention, severe haematuria, or other emergency presentations, attend A&E or call 999.
